Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTRENASDAQ:GHNASDAQ:RDNTNASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTREFortrea$4.18+0.7%$5.82$3.99▼$28.41$375.58M2.151.80 million shs2.22 million shsGHGuardant Health$38.19-2.5%$42.95$20.14▼$52.92$4.73B1.492.14 million shs1.65 million shsRDNTRadNet$55.29-2.5%$53.19$45.00▼$93.65$4.15B1.46686,610 shs525,668 shsVCYTVeracyte$26.72-4.5%$30.21$19.73▼$47.32$2.19B2.14896,149 shs1.07 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTREFortrea+0.72%-0.48%-31.25%-70.25%-83.41%GHGuardant Health-2.50%+2.97%-20.42%-9.31%+45.99%RDNTRadNet-2.45%-4.77%+8.35%-4.01%-6.93%VCYTVeracyte-4.47%-3.22%-15.63%-21.04%+24.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTREFortrea3.0414 of 5 stars3.91.00.00.02.10.82.5GHGuardant Health4.5899 of 5 stars4.51.00.04.34.02.50.6RDNTRadNet4.3299 of 5 stars3.73.00.04.63.52.50.0VCYTVeracyte4.3786 of 5 stars4.43.00.04.33.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTREFortrea 1.86Reduce$15.00258.85% UpsideGHGuardant Health 3.05Buy$52.3236.99% UpsideRDNTRadNet 3.40Buy$69.7526.15% UpsideVCYTVeracyte 2.70Moderate Buy$40.9053.07% UpsideCurrent Analyst Ratings BreakdownLatest RDNT, VCYT, FTRE, and GH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025FTREFortreaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/14/2025FTREFortreaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.005/14/2025FTREFortreaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.005/13/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025GHGuardant HealthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.005/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $57.005/2/2025FTREFortreaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$7.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTREFortrea$2.69B0.14$0.67 per share6.28$19.58 per share0.21GHGuardant Health$774.00M6.11N/AN/A$1.34 per share28.50RDNTRadNet$1.87B2.22$2.94 per share18.81$11.79 per share4.69VCYTVeracyte$463.39M4.52$0.06 per share442.29$14.30 per share1.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTREFortrea-$3.40M-$8.79N/A3.271.78-10.99%2.00%0.80%8/11/2025 (Estimated)GHGuardant Health-$479.45M-$3.39N/AN/AN/A-59.05%-19,157.20%-25.96%8/6/2025 (Estimated)RDNTRadNet$3.04M-$0.43N/A104.32N/A-0.25%4.29%1.45%8/5/2025 (Estimated)VCYTVeracyte-$74.40M$0.41N/A37.11N/A-2.18%3.02%2.80%8/5/2025 (Estimated)Latest RDNT, VCYT, FTRE, and GH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025FTREFortrea-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million3/3/2025Q4 2024FTREFortrea$0.36$0.18-$0.18-$0.68$703.22 million$697.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTREFortreaN/AN/AN/AN/AN/AGHGuardant HealthN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTREFortrea0.741.181.18GHGuardant HealthN/A6.225.85RDNTRadNet0.892.162.16VCYTVeracyteN/A5.084.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTREFortreaN/AGHGuardant Health92.60%RDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipFTREFortrea0.12%GHGuardant Health6.10%RDNTRadNet5.12%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTREFortrea18,00090.50 million89.59 millionOptionableGHGuardant Health1,790123.89 million116.76 millionNot OptionableRDNTRadNet8,97075.03 million70.24 millionOptionableVCYTVeracyte79078.32 million76.49 millionOptionableRDNT, VCYT, FTRE, and GH HeadlinesRecent News About These CompaniesVeracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCOMay 29 at 12:57 AM | insidermonkey.comVeracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer ResearchMay 28 at 4:18 PM | businesswire.comVeracyte: Upgrading To NeutralMay 26 at 10:32 AM | seekingalpha.comPalisades Investment Partners LLC Acquires New Position in Veracyte, Inc. (NASDAQ:VCYT)May 24, 2025 | marketbeat.comMan Group plc Sells 294,029 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 23, 2025 | marketbeat.comDeutsche Bank AG Has $3.22 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 23, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Nuveen Asset Management LLCMay 22, 2025 | marketbeat.comComparing Veracyte (NASDAQ:VCYT) and Grail (NASDAQ:GRAL)May 22, 2025 | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Virtus Investment Advisers Inc.May 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Lowers Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 21, 2025 | marketbeat.comVeracyte to Participate in Upcoming Investor ConferencesMay 20, 2025 | businesswire.comPoint72 Asset Management L.P. Buys Shares of 523,162 Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $7.61 Million Position in Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Bank of America Corp DEMay 20, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 55,684 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comVeracyte Stock Surges 30.9% in a Year: What's Driving the Rally?May 19, 2025 | zacks.comLazard Asset Management LLC Boosts Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 19, 2025 | marketbeat.comResearch Analysts Set Expectations for Veracyte Q2 EarningsMay 18, 2025 | marketbeat.comParkman Healthcare Partners LLC Reduces Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 16, 2025 | marketbeat.comGranahan Investment Management LLC Has $1.96 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 13, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Fred Alger Management LLCMay 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRDNT, VCYT, FTRE, and GH Company DescriptionsFortrea NASDAQ:FTRE$4.18 +0.03 (+0.72%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$4.24 +0.07 (+1.56%) As of 05/28/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.Guardant Health NASDAQ:GH$38.19 -0.98 (-2.50%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$38.58 +0.40 (+1.03%) As of 05/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.RadNet NASDAQ:RDNT$55.29 -1.39 (-2.45%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$56.23 +0.94 (+1.70%) As of 05/28/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$26.72 -1.25 (-4.47%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$27.65 +0.93 (+3.50%) As of 05/28/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
